Succinat-Semialdehyd-Dehydrogenase-Mangel: eine vererbbare neurometabolische Erkrankung

M. Gahr; B. J. Connemann; C. J. Schönfeldt-Lecuona; R. W. Freudenmann

doi:10.1055/s-0032-1330544

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2013; 81(3): 154-161
DOI: 10.1055/s-0032-1330544

Übersicht

Succinat-Semialdehyd-Dehydrogenase-Mangel: eine vererbbare neurometabolische Erkrankung

Succinic Semialdehyde Dehydrogenase Deficiency: An Inheritable Neurometabolic Disease

Authors

M. Gahr
B. J. Connemann
C. J. Schönfeldt-Lecuona
R. W. Freudenmann

Abstract

Zusammenfassung

Succinat-Semialdehyd-Dehydrogenase-Mangel (SSADHD) ist eine neurometabolische Erkrankung mit autosomal-rezessivem Erbgang. Gegenwärtig sind weltweit zwar nur ca. 450 Fälle bekannt, dennoch gehört der SSADHD zu den häufigen pädiatrisch relevanten Störungen des Neurotransmitterstoffwechsels. SSADHD liegt eine Mutation im Aldh5a1-Gen zugrunde, was zu einer gestörten Funktion der Succinat-Semialdehyd-Dehydrogenase führt. Dadurch kommt es zu einer Akkumulation von γ-Aminobuttersäure und Succinat-Semialdehyd, welches bei SSADHD alternativ mittels der Succinat-Semialdehyd-Reduktase zu γ-Hydroxy-Buttersäure metabolisiert wird. Der klinische Phänotyp ist unspezifisch mit ausgeprägter interindividueller Varianz. Motorische und sprachliche Entwicklungsverzögerung sowie Epilepsie, Intelligenzminderung, Schlafstörung, Ataxie, muskuläre Hypotonie und Verhaltensauffälligkeiten sind jedoch häufig. Erste Symptome treten häufig bereits im ersten Lebensjahr auf, während die Erkrankung insgesamt eher statisch verläuft. Gegenwärtig existieren keine kausalen Therapieoptionen.

Abstract

Succinic semialdehyde dehydrognase deficiency (SSADHD) is a neurometabolic disease with autosomal recessive inheritance. Although only about 450 cases are known worldwide, SSADHD is a frequent paediatric disorder of the neurotransmitter metabolism. SSADHD is caused by a mutation of the Aldh5a1-gene resulting in a dysfunction of the enzyme succinic semialdehyde dehydrogenase. This is followed by an accumulation of γ-aminobutyric acid and succinic semialdehyde that is alternatively metabolised via succinic semialdehyde reductase to γ-hydroxybutyric acid. The clinical phenotype is unspecific with pronounced interindividual variability. However, delayed acquisition of motor and language developmental milestones as well as epilepsy, mental retardation, sleep disorder, ataxia, muscle hypotonia, and behavioural disturbances are frequent. First symptoms frequently occur in the first year of life while the general course of the disease is non-progressive. Currently, no causal therapy exists.

Schlüsselwörter

Autismus - GABA - GHB - Neurotransmitter - 4-Hydroxy-Buttersäure-Azidurie

Key words

autism - GABA - GHB - neurotransmitter - 4-hydroxybutyric aciduria

Full Text

References

Literatur
1 Kim K, Pearl P, Jensen K et al. Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance. Antioxid Redox Signal 2011; 15: 691-718
2 Gibson K, Baumann C, Ogier H et al. Pre- and postnatal diagnosis of succinic semialdehyde dehydrogenase deficiency using enzyme and metabolite assays. J Inherit Metab Dis 1994; 17: 732-737
3 Cash C, Maitre M, Mandel P. Purification from human brain and some properties of two NADPH-linked aldehyde reductases which reduce succinic semialdehyde to 4-hydroxybutyrate. J Neurochem 1979; 33: 1169-1175
4 Pearl P, Novotny E, Acosta M et al. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 2003; 54 (Suppl. 06) 73-80
5 Gibson K, Gupta M, Pearl P et al. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol Psychiatry 2003; 54: 763-768
6 Gibson K, Christensen E, Jakobs C et al. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 1997; 99: 567-574
7 Sedel F, Baumann N, Turpin J et al. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30: 631-641
8 Jakobs C, Bojasch M, Mönch E et al. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta 1981; 111: 169-178
9 Gibson K, Jakobs C. Disorders of beta- and alpha-amino acids in free and peptide-linked forms. In: Scriver C, Beaudet A, Sly W, et al. (eds) The metabolic and molecular bases of inherited disease. 8 ed. New York: McGraw-Hill; 2001: 2079-2105
10 Pearl P, Gibson K, Cortez M et al. Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men. J Inherit Metab Dis 2009; 32: 343-352
11 Gibson K, Jakobs C, Pearl P et al. Murine succinate semialdehyde dehydrogenase (SSADH) deficiency, a heritable disorder of GABA metabolism with epileptic phenotype. IUBMB Life 2005; 57: 639-644
12 Pearl P, Taylor J, Trzcinski S et al. The pediatric neurotransmitter disorders. J Child Neurol 2007; 22: 606-616
13 Opladen T, Hoffmann G, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalalinaemia. J Inherit Metab Disord 2012; 35: 963-973
14 Hennermann J, Berger J, Grieben U et al. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Disord 2012; 35: 253-261
15 Bok L, Halbertsma F, Houterman S et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2012; 54: 849-854
16 Knerr I, Gibson K, Jakobs C et al. Neuropsychiatric morbidity in adolescent and adult succinic demialdehyde dehydrogenase deficiency patients. CNS Spectr 2008; 13: 598-605
17 Jakobs C, Smit L, Knerr I et al. The first adult case with 4-hydroxybutyric aciduria. J Inherit Metab Dis 1990; 13: 341-344
18 Amberger J, Bocchini C, Scott A et al. McKusick’s Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 2009; 37: D793-D796
19 Pearl P, Gibson K, Acosta M et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003; 60: 1413-1417
20 Trettel F, Malaspina P, Jodice C et al. Human succinic semialdehyde dehydrogenase. Molecular cloning and chromosomal localization. Adv Exp Med Biol 1997; 414: 253-260
21 Chambliss K, Hinson D, Trettel F et al. Two exon-skipping mutations as the molecular basis of succinic semialdehyde dehydrogenase deficiency (4-hydroxy aciduria). Am J Med Gen 1998; 63: 399-408
22 Aoshima T, Kajita M, Sekido Y et al. Mutation analysis in a patient with succinic demialdehyde dehydrogenase deficiency: a compound heterozygote with 103-121del and 1460T > A of the ALDH5A1 gene. Hum Hered 2002; 53: 42-44
23 Akaboshi S, Hogema B, Novelletto A et al. Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 2003; 22: 442-450
24 Bekri S, Fossoud C, Plaza G et al. The molecular basis of succinic semialdehyde dehydrogenase deficiency in one family. Mol Genet Metab 2004; 81: 347-351
25 Blasi P, Palmerio F, Caldarola S et al. Succinic semialdehyde dehydrogenase deficiency: clinical, biochemical and molecular characterization of a new patient with severe phenotype and a novel mutation. Clin Genet 2006; 69: 294-296
26 Kwok J, Yuen C, Law L et al. A novel ALDH5A1 mutation in a patient with succinic semialdehyde dehydrogenase deficiency. Pathology 2012; 44: 280-282
27 Gibson K, Doskey A, Rabier D et al. Differing clinical presentation of succinic semialdehyde dehydrogenase deficiency in adolescent siblings from Lifu Island, New Caledonia. J Inherit Metab Dis 1997; 20: 370-374
28 Al-Essa M, Bakheet S, Patay Z et al. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patients with 4-hydroxybutyric aciduria; a progressive neurometabolic disease. Brain Dev 2000; 22: 127-131
29 Yalcinkaya C, Gibson K, Gubduz E et al. MRI findings in succinic semialdehyde dehydrogenase deficiency. Neuropediatrics 2000; 31: 45-46
30 Albers R, Koval G. Succinic semialdehyde dehydrogenase: purification and properties of the enzyme from monkey brain. Biochim Biophys Acta 1961; 52: 29-35
31 Thauer R. Citric-acid cycle, 50 years on. Modifications and an alternative pathway in anaerobic bacteria. Eur J Biochem 1988; 176: 497-508
32 Gibson K, Hoffmann G, Hodson A et al. 4-hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 1998; 29: 14-22
33 Scriver C, Gibson K. Disorders of beta- and gamma-amino acids in free and peptide-linked forms. In: Scriver C, Beaudet A, Sly W, et al. (eds) The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995: 1349-1368
34 Pearl P, Acosta M, Wallis D et al. Dyskinetic features of succinate semialdehyde dehydrogenase deficiency, a GABA degradative defect. In: Fernandez-Alvarez E, Arzimanoglou A, Tolosa E, (eds) Paediatric Movement Disorders. Montrouge, France: John Libbey Eurotext; 2005
35 Vogel K, Pearl P, Theodore W et al. Thirty years beyond discovery-Clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. J Inherit Metab Dis 2012; 28 [Epub ahead of print]
36 Doherty J, Hattox S, Snead O et al. Identification of endogeneous y-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig, and rhesus monkey brain. J Pharmacol Exp Ther 1978; 207: 130-139
37 Smith D. Tranylcypromine stereoisomers, monoaminergic neurotransmission and behavior. A minireview. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 130-136
38 Gervasi N, Monnier Z, Vincent P et al. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003; 23: 11469-11478
39 Wu Y, Ali S, Ahmadian G et al. Gamma-hydroxybutyric acid (GHB) and y-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004; 47: 1146-1156
40 Lingenhoehl K, Brom R, Heid J et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 1999; 38: 1667-1673
41 Wong C, Gibson K, Snead 3rd O. Gamma-hydroxybutyric acid (GHB): from the street to the brain: neurobiology of a recreational drug. Trends Pharmacol Sci 2004; 25: 29-34
42 Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-361
43 Snead 3rd O, Gibson K. Gamma-Hydroxybutyric acid. N Engl J Med 2009; 352: 2721-2732
44 Snead 3rd O. Gamma-hydroxybutyric and absence seizure activity. In: Tunnicliff G, Cash C, (eds) Gamma-hydroxybutyrate: molecular, functional and clinical aspects. London: Taylor and Francis; 2002: 132-149
45 Buzzi A, Wu Y, Frantseva M et al. Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res 2006; 1090: 15-22
46 Wong C, Gibson K, Snead 3rd O. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004; 25: 29-34
47 Adamowicz P, Kała M. Simultaneous screening for and determination of 128 date-rape drugs in urine by gas chromatography-electron ionization-mass spectrometry. Forensic Sci Int 2010; 198: 39-45
48 Knerr I, Pearl P, Bottiglieri T et al. Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1–/– mice and characterization of gamma-hydroxybutyric acid pharmacology. J Inherit Metab Dis 2007; 30: 279-294
49 Ren X, Mody I. Gamma-hydroxybutyrate reduces mitogen-activated protein kinase phosphorylation via GABAB receptor activation in mouse frontal cortex and hippocampus. J Biol Chem 2003; 278: 42006-42011
50 Donarum E, Stephan D, Larkin K et al. Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2006; 29: 143-156
51 Bak L, Schousboe A, Waagepetersen H. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006; 98: 641-653
52 Berton F, Brancucci A, Beghè F et al. Gamma-Hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slice. Eur J Pharmacol 1999; 380: 109-116
53 Hogema B, Gupta M, Senephansiri H et al. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat Genet 2001; 29: 212-216
54 Gupta M, Polinsky M, Senephansiri H et al. Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency. Neurobiol Dis 2004; 16: 556-562
55 Stewart L, Nylen K, Persinger M et al. Circadian distribution of generalized tonic-clonic seizures associated with murine succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Epilepsy Behav 2008; 13: 290-294
56 Wu Y, Buzzi A, Frantseva M et al. Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Ann Neurol 2006; 59: 42-52
57 Pearl P, Reehal T, Drillings I et al. Succinic Semialdehyde Dehydrogenase Deficiency. In: Pagon R, Bird T, Dolan C, et al. (eds) GeneReviews™. Seattle: University of Washington, Seattle; 1993–2004 May 05 [updated 2010 Oct 05]
58 Pearl P, Capp P, Novotny E et al. Inherited disorders of neurotransmitters in children and adults. Clin Biochem 2005; 38: 1051-1058
59 Pearl P, Gibson K. Clinical aspects of the disorders of GABA metabolism in children. Curr Opin Neurol 2004; 17: 107-113
60 Pearl P, Acosta M, Wallis D et al. Dyskinetic features of succinate semialdehyde dehydrogenase deficiency, a GABA degenerative defect. In: Alvarez E, Arzimanoglu A, Tolosa E, (eds) Paediatric movement disorders: progress in understanding. Surrey, United Kingdom: John Libbey Eurotext; 2005: 203-212
61 Arnulf I, Konofal E, Gibson K et al. Effect of genetically caused excess of brain gamma-hydroxybutyric acid and GABA on sleep. Sleep 2005; 28: 418-424
62 Philippe A, Deron J, Genevieve D et al. Neurodevelopmental pattern of succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria). Dev Med Child Neurol 2004; 46: 564-568
63 Pearl P, Shamim S, Theodore W et al. Polysomnographic abnormalities in succinic semialdehyde dehydrogenase (SSADH) deficiency. Sleep 2009; 32: 1645-1648
64 Ziyeh S, Ansgar B, Korinthenberg R et al. Selective involvement of the globus pallidus and dentate nucleus in succinic semialdehyde dehydrogenase deficiency. Pediatr Radiol 2002; 32: 598-600
65 Yalcinkaya C, Gibson K, Gündüz E et al. MRI findings in succinic semialdehyde dehydrogenase deficiency. Neuropediatrics 2000; 31: 45-46
66 Brismar J, Ozand P. CT and MR of the brain in disorders of the proprionate and methylmalonate metabolism. Am J Neuroradiol 1994; 15: 1459-1473
67 Harting I, Neumaier-Probst E, Seitz A et al. Dynamic changes of striatal and extrastriatal abnormalities in glitaric aciduria type I. Brain 2009; 132 (07) 1764-1782
68 Pearl P, Taylor J, Trzcinski S et al. 11C-Flumazenil PET imaging in patients with SSADH deficiency. J Inherit Metab Dis 2007; 30 (Suppl. 01) 43
69 Pearl P, Gibson K, Quezado Z et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology 2009; 73: 423-429
70 Knerr I, Gibson K, Murdoch G et al. Neuropathology in succinic semialdehyde dehydrogenase deficiency. Pediatr Neurol 2010; 42: 255-258
71 Bonham J, Downing M, Pollitt R et al. Quality assessment of urinary organic acid analysis. Ann Clin Biochem 1994; 31: 129-133
72 Gibson K, Aramaki S, Sweetman L et al. Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom 1990; 19: 89-93
73 Gibson K, Sweetman L, Nyhan W et al. Defective succinic semialdehyde dehydrogenase activity in 4-hydroxybutyric aciduria. Eur J Pediatr 1984; 142: 257-259
74 Gibson K, Lee C, Chambliss K et al. 4-Hydroxybutyric aciduria: application of a fluorometric assay to the determination of succinic semialdehyde dehydrogenase activity in extracts of cultured human lymphoblasts. Clin Chim Acta 1991; 196: 219-221
75 Medina-Kauwe L, Tobin A, DeMeirleir L et al. 4-Aminobutyrateaminotransferase (GABA-transaminase) deficiency. J Inherit Metab Dis 1999; 22: 414-427
76 Rogawski M, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-564
77 Gropman A. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003; 54 (Suppl. 06) 66-72
78 Pearl P, Gropman A. Monitoring gamma-hydrocybutyric acid levels in succinate-semialdehyde dehydrogenase deficiency. Ann Neurol 2004; 55: 599
79 Jakobs C, Michael T, Jaeger E et al. Further evaluation of vigabatrin therapy in 4-hydroxybutyric aciduria. Eur J Pediatr 1992; 151: 466
80 Gibson K, deVivo D, Jakobs C. Vigabatrin therapy in patient with succinic semialdehyde dehydrogenase deficiency. Lancet 1989; 2: 1105-1106
81 Jaeken J, Casaer P, deCock P et al. Vigabatrin in GABA metabolism disorders. Lancet 1989; 1: 1074
82 Uziel G, Bardelli P, Pantaleoni C et al. Hydroxybutyric aciduria: clinical findings and vigabatrin therapy. J Inherit Metab Dis 1993; 16: 520-522
83 Ergezinger K, Jeschke R, Frauendienst-Egger G et al. Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003; 54: 686-689
84 Escalera G, Ferrer I, Marina L et al. Succinic semialdehyde dehydrogenase deficiency: decrease in 4-OH-butyric acid levels with low doses of vigabatrin. An Pediatr 2010; 72: 128-132
85 Casarano M, Alessandri M, Salomons G et al. Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis (JIMD Reports) 2011; 2: 119-123
86 Matern D, Lehnert W, Gibson K et al. Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). J Inherit Metab Dis 1996; 19: 313-318
87 Leon R, Wu H, Jin Y et al. Protective function of taurine in glutamate-induced apoptosis in cultures neurons. J Neurosci Res 2008; 87: 1185-1194
88 El Idrissi A, Messing J, Scalia J et al. Prevention of epileptic seizures by taurine. Adv Exp Med Biol 2003; 526: 515-525
89 Gupta M, Greven R, Jansen E et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenas (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther 2002; 302: 180-187
90 Saronwala A, Tournay A, Gargus J. Taurine treatment of succinate semialdehyde dehydrogenase (SSADH) deficiency reverses MRI-documented globus lesion and clinical syndrome. In, 15th Ann Clin Genet Meeting. Phoenix AZ USA: Am Coll Med Genet; 2008: 103
91 Pearl P, Theodore W, McCarter R et al. Taurine intervention in succinic semialdehyde dehydrogenase deficiency: an open label trial. Molec Genet Metab 2012; 105: 346 , abstract
92 McNally M, Hartman A. Ketone bodies in epilepsy. J Neurochem 2012; 121: 28-35
93 Cusmai R, Martinelli D, Moavero R et al. Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. Eur J Paediatr Neurol 2012; 2012
94 Nylen K, Velazquez J, Sayed V et al. The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1(–/–) mice. Biochim Biophys Acta 2009; 1790: 208-212
95 Nylen K, Velazquez J, Likhodii S et al. A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Exp Neurol 2008; 210: 449-457
96 Hogema B, Akaboshi S, Taylor M et al. Prenatal diagnosis of succinic semialdehyde dehydrogenase deficiency: increased accuracy employing DNA, enzyme, and metabolite analyses. Mol Genet Metab 2001; 72: 218-222
97 Froestl W, Gallagher M, Jenkins H et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004; 15: 1479-1487